Dossier assessment

Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A25-54
Last updated

Report documents

  1. Extract of dossier assessment

    Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 409 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-54_en
  2. Dossier assessment

    Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 740 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-54

Dossier assessment

Indication:

Adult patients with unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment

Result of dossier assessment:

Added benefit not proven

Additional information

Federal Joint Committee (G-BA)

2025-10-16 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A25-54
Commission
Commission awarded on 28.04.2025 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-54_en

Connected Projects

  1. Dossier assessment

    Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-80
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-81
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-07
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Trastuzumab deruxtecan (gastric cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-08
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Trastuzumab deruxtecan (NSCLC) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-115
    Last updated

    Status: Commission completed

  6. Addendum

    Trastuzumab deruxtecan (breast cancer) – Addendum to Project A25-54

    Project no.
    A25-116
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Trastuzumab deruxtecan (gastric or gastroesophageal junction adenocarcinoma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-128
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form